Surgical Innovations (SUN)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 12.6 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.50 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +11.1% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Surgical Innovations Group Plc revenues remained flat at L7.6M. Net income decreased 61% to L686K. Revenues reflect market conditions. Net income was partially offset by Finance costs increase of 29% to L94K (expense), Finance income decrease of 64% to L4K (income). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 0 | 2 |
Surgical Innovations Group plc is a holding company. The Company’s principal activities include design, development and manufacture of devices for use in minimally invasive surgery (MIS) and industrial markets. Surgical devices are targeted at the operating theatre environment in public and private hospitals. The Company’s segments include: SI Brand, OEM and Industrial. The principal activities of the SI Brand are the research, development, manufacture and distribution of SI branded minimally invasive devices. The principal activities of the OEM are the research, development, manufacture and distribution of minimally invasive devices for third party medical device companies through either own label or co-branding. The principal activities of the industrial segment are the research, development, manufacture and sale of minimally invasive technology products for industrial application.
Directors: N.Graham Bowland (CEO) , Michael Thornton (CFO) ,
No. of Employees: 104 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 404,591,902 |
| Free Float | 241.8m (59.8%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Clayton Wood House6 Clayton Wood Bank, LEEDS, LS16 6QZ, United Kingdom |
| Web | http://www.surginno.com/ |
| Phone | +44 113 2307597 |
| Contact | N. Graham Bowland (Secy.) |
| Registrar | Capita Registrars (Ilford) |
| Auditors | Grant Thornton UK LLP |
| 8th May | Snr Appointment of President US Sales & Operations |
| 17th Apr | Appointment to the Clinical Advisory Board |
| 9th Apr | Preliminary Results |
| 18th Mar | Change of Adviser |
| 11th Mar | US appointment to ICAB |
| 19th Feb | Trading Update |
Recent ↓
